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Abstract
Aplasia cutis congenita (ACC) manifests with localized skin defects at birth of unknown cause, mostly affecting the scalp
vertex. Here, genome-wide linkage analysis and exome sequencing was used to identify the causative mutation in
autosomal dominant ACC. A heterozygous Arg-to-His missense mutation (p.R930H) in the ribosomal GTPase BMS1 is
identified in ACC that is associated with a delay in 18S rRNA maturation, consistent with a role of BMS1 in processing of pre-
rRNAs of the small ribosomal subunit. Mutations that affect ribosomal function can result in a cell cycle defect and ACC skin
fibroblasts with the BMS1 p.R930H mutation show a reduced cell proliferation rate due to a p21-mediated G1/S phase
transition delay. Unbiased comparative global transcript and proteomic analyses of ACC fibroblasts with this mutation
confirm a central role of increased p21 levels for the ACC phenotype, which are associated with downregulation of
heterogenous nuclear ribonucleoproteins (hnRNPs) and serine/arginine-rich splicing factors (SRSFs). Functional enrichment
analysis of the proteomic data confirmed a defect in RNA post-transcriptional modification as the top-ranked cellular
process altered in ACC fibroblasts. The data provide a novel link between BMS1, the cell cycle, and skin morphogenesis.
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Introduction
Aplasia cutis congenita (ACC [MIM 107600]) manifests at birth
as a localized skin defect that usually heals with a hypertrophic scar.
Most commonly the scalp skin is affected and results in localized
alopecia at the site of the defect, but sometimes the defect can
extend into deeper structures involving the dura mater or osseous
structures. ACC has to be distinguished clinically from birth trauma
orintrauterineherpeticinfections.Most reportedcasesaresporadic,
but autosomal dominant inheritance has been reported as well [1].
A causative gene mutation for non-syndromic ACC has not been
reported so far. While the majority of patients with aplasia cutis
have no other congenital abnormalities, aplasia cutis can occur as
part of rare syndromes with a wide spectrum of anomalies. For
example, some patients with Johanson-Blizzard syndrome [MIM
243800] have been reported to have aplasia cutis of the scalp skin.
This syndrome is characterized by nasal alar hypoplasia, hypothy-
roidism,pancreaticachyliaandcongenitaldeafness andiscausedby
a mutation in the UBR1 gene [2]. Adams-Oliver syndrome (AOS
[MIM 100300]) is characterized by ACC and transverse limb
defects, but a wide range of additional congenital anomalies have
been reported in patients with AOS, including congenital heart
defects. Recently gain-of-function mutations in the ARHGAP31
gene encoding a Cdc42/Rac1 regulatory protein have been
reported in AOS [3], and two more cases of AOS were reported
to harbor homozygous mutations in the DOCK6 gene, encoding a
guanidine nucleotide exchange factor that activates Cdc42 and rac1
[4]. A recent report showed mutations in the transcriptional
regulator of the Notch pathway, RBPJ, in two small families with
AOS [5]. Furthermore, mutations in the KCTD1 gene were recently
reported in patients with Scalp-Ear-Nipple syndrome, which
manifests with scalp ACC lesions as well [6]. However, the majority
of individuals with aplasia cutis have no other congenital anomalies,
suggesting a distinct pathomechanism between non-syndromic
ACC and syndromic cases as in AOS or other syndromes in which
aplasia cutis has been described.
Histologically, ACC shows in most cases a complete absence of
epidermis at birth suggesting a skin morphogenesis defect. It has
been speculated that a defect in cell proliferation may be underlying
ACC that may lead to a delay in skin closure ability late during
development at an anatomic site where a steady expansion of the
brain structures may require a rapid proliferation of the overlying
skin. However, neither the genetic basis for ACC nor the
pathomechanisms that result in the skin formation defects are
known. Identifying the genetic causes for ACC and determining
their molecular consequences promises to reveal new mechanisms
that govern skin morphogenesis during development. Here, by
combining genome-wide linkage analysis with exome sequencing
approaches, a mutation in the ribosomal GTPase BMS1 is
identified in autosomal dominant ACC that is associated with a
p21-mediated G1/S phase cell cycle transition delay and results in a
reduced cell proliferation rate. In addition, unbiased expression
profiling and proteomic analyses in fibroblasts carrying this
mutation independently confirm a central role of a p21-mediated
G1/S phase cell cycle delay for the ACC phenotype.
Results
A mutation in the ribosomal GTPase BMS1 causes
autosomal-dominant ACC
In this study, a five-generation family with autosomal dominant
inheritance of ACC was identified (Fig. 1a). In this family the
PLOS Genetics | www.plosgenetics.org 1 June 2013 | Volume 9 | Issue 6 | e1003573exclusive congenital anomaly is a localized absence of skin at the
vertex and occipital area of the scalp that most often healed with a
hypertrophic scar (Fig. 1a). No other congenital anomalies were
identified, excluding rare syndromes that can manifest with ACC
[2,3,4].
Genome-wide linkage analysis revealed a single genomic region
with a LOD score.2 on chromosome 10q11. The maximal LOD
score of 2.709 was reached with a sharp peak between marker
rs1359280 located at 34,877,513 bp and marker rs7071514
located at 49,518,113 bp (Fig. 1b) (an additional affected family
member who carried the disease allele was born after the linkage
study was completed, which further increased the LOD score).
Haplotypes and recombination sites were independently con-
firmed using microsatellite markers. Whole-exome sequencing was
performed in one affected individual of this family. Sequencing of
coding regions was performed to a mean coverage of 1516 to
generate 17.3 Gb of sequence. Variants were filtered to exclude
homozygous base pair changes, non-coding variants, synonymous
variants and all non-synonymous changes that are present in
dbSNP129, the 1000genomes database and the NHLBI Exome
Sequencing Project (ESP) database. This genome-wide sequencing
approach resulted in the identification of a single non-synonymous
heterozygous G.A base change within the linked genomic region.
This sequence change was not identified in 5,351 unrelated
individuals for which high-quality sequence calls were made at this
position in the ESP sequence data, suggesting that the G.A
sequence change is not a rare variant but pathogenic in this family
with ACC. Bidirectional Sanger sequencing was performed in all
members of this family, showing that none of the unaffected family
members had the G.A sequence change, but all affected family
members had this sequence change, thus co-segregating with the
disease allele. Finally, sequencing of DNA from 100 geographically
and ethnically matched unaffected control individuals did not
reveal this mutation as well.
This heterozygous G.A mutation results in an Arg-to-His amino
acid change at position 930 (p.R930H) of a conserved Arginine within
the C-terminal domain of the ribosome assembly GTPase BMS1,
which has previously not been implicated in skin morphogenesis
(Figure 1c–1e). BMS1 is a component of the U3 snoRNA-containing
complex that has been shown to be essential in yeast and to be
conserved in eukaryotes. Depletion of BMS1 interferes with pre-
ribosomal RNA (rRNA) processing at sites A0,A 1 and A2 and the
formation of the 40S ribosomal subunit [7,8]. Biochemical analyses
demonstrated that BMS1 may function as a GTPase, with its GTPase
activity located at the N-terminus of the protein. In addition to binding
to U3 snoRNA, BMS1 binds the endonuclease Rcl1 in a GTP-
dependent manner and BMS1 binding is required to recruit Rcl1 to
preribosomes. Thus, it has been suggested that BMS1 functions as a
GTP-regulated switch to deliver Rcl1 to preribosomes and has an
essential role in the formation of the small ribosomal subunit [9,10].
The C-terminal domain of BMS1 has been proposed to act as a
putative intramolecular GTPase-activating protein (GAP) domain and
is separated from the rest of the protein by a flexible linker region [9].
However, the in vivo consequences of an impairment of this putative
GAP domain for cellular functions have not been defined, and the
BMS1 p.R930H mutation in ACC provides the first indication for a
role of this domain for overall BMS1 function in vivo.
ACC skin fibroblasts with the BMS1 p.R930H mutation
show a delay in pre-rRNA processing
BMS1 is ubiquitously expressed, including the proliferative
developing skin of the scalp that is affected in ACC (Fig. 1f, 1g).
The BMS1 p.R930H mutation within the putative GAP domain
does not affect BMS1 expression or its nucleolar localization (Fig.
S1). Due to the heterozygous nature of the mutation within a
regulatory domain of BMS1 with a remaining wild-type allele and
the only localized congenital defect in ACC, it would be expected
that the p.R930H mutation in BMS1 leads to rather modest
abnormalities in pre-rRNA processing and therefore results in a
restricted phenotype. Indeed, pulse-chase labeling experiments
with ACC
BMS1(p.R930H) fibroblasts (isolated from an affected
member of this family) and with matched unrelated wild-type
fibroblasts, in which labeling of pre-rRNAs was performed with L-
[methyl-
3H]methionine, showed formation of all pre-rRNAs but
with higher levels of persistent 45S pre-rRNA and the pre-rRNA
band likely corresponding to the 30S pre-rRNA in
ACC
BMS1(p.R930H) fibroblasts (Fig. 2a–2c). Northern blotting
experiments using RNA from ACC
BMS1(p.R930H) fibroblasts and
control fibroblasts with probes for ITS-1, ETS-1 and ITS-2
(transcribed spacers) showed an increase of 45S and 30S pre-
rRNAs in mutant cells and a relative decrease of 21S and 18S-E
pre-rRNAs (precursors for 18S rRNA of the small ribosomal
subunit), while 32S and 12S pre-rRNAs (precursors for 5.8S and
28S rRNAs of the large ribosomal subunit) were not affected
(Fig. 2d, Fig. S2). The findings of the pulse-chase labeling and
Northern blotting experiments in ACC
BMS1(p.R930H) fibroblasts are
consistent with a delay in pre-rRNA processing affecting the small
ribosomal subunit, as would be predicted based on the reported
role of BMS1 for the small ribosomal subunit processome in yeast
[7,8].
Similarly, inducible shRNA-mediated stable knockdown of
BMS1 to achieve ,40–50% of BMS1 transcript levels (to
correspond to heterozygous BMS1 cells) resulted also in a relative
increase of 45S and 30S pre-rRNAs, and a relative decrease in 21S
and 18S-E pre-rRNAs, while 32S pre-rRNAs were reduced less
when compared to the 30S pre-rRNAs (Fig. 2d and Fig. S2). These
findings suggest that the BMS1 p.R930H mutation results in a
reduced activity of BMS1 during the processing of 18S pre-
rRNAs.
A p21-mediated G1/S phase transition defect in ACC skin
fibroblasts with the BMS1 p.R930H mutation
Mutations in several genes that affect ribosomal function have
been described to result in a G1/S phase transition delay that may
involve p53-dependent and p53-independent pathways, presum-
ably due to ‘‘nucleolar stress’’ resulting from increased free
Author Summary
Elucidating the pathomechanisms in congenital diseases
of the skin provides the opportunity to learn what cellular
processes are important during embryonic development
of the skin structures. Aplasia cutis congenita (ACC)
manifests with localized skin defects, most commonly
affecting the scalp skin. Here, global proteomic and
transcriptional analyses are combined with genome-wide
linkage and exome sequencing approaches to identify the
molecular mechanisms involved in ACC. A mutation in the
ribosomal GTPase BMS1 is identified in ACC that affects
18S rRNA maturation. This mutation is associated with a
p21-mediated G1/S phase transition delay during the cell
cycle that inhibits cell proliferation. The findings are
consistent with mutations in ribosomal disorders that
result in nucleolar stress and a G1/S phase transition delay.
Thus, mutations in BMS1 can affect the formation of a
highly proliferative tissue during development, such as the
rapidly expanding scalp epidermis.
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assembly abnormalities [11]. To determine whether ACC
fibroblasts that carry the BMS1 p.R930H mutation show a similar
cellular response as in some ribosomopathies, these fibroblasts
were examined for their proliferation rate and whether a G1/S
phase transition delay can be observed.
Skin fibroblasts were isolated from an affected family member
through a skin biopsy and expanded in vitro. Control fibroblasts
were obtained from an unrelated unaffected individual, matched
for ethnicity, age and anatomic location. Subconfluent early-
passage ACC fibroblasts and control fibroblasts were analyzed for
their cell cycle status, cell proliferation rate and cell migration
ability. FACS-based cell cycle analysis showed a G1/S phase
transition defect in ACC fibroblasts (Fig. 3a), with a significantly
reduced cell proliferation rate (Fig. 3b). Furthermore, cell
migration rate was increased in ACC fibroblasts in an in vitro
scratch assay, which is consistent with the observation that cell
migration is favored in G1 phase (Fig. 3c) [12].
Figure 1. A mutation in the ribosome biogenesis GTPase BMS1 causes autosomal-dominant ACC. a. Representative images of
individuals with ACC in a five-generation pedigree with autosomal dominant inheritance pattern and full penetrance. (Left image: 1 year old with
hypertrophic scar at site of congenital ACC of the scalp; Middle image: father of 1 year old of left image with scar at site of congenital ACC; Right
image: daughter of this father on day 1 after birth with localized erosion on vertex of scalp (indicated with arrow in pedigree; this member was born
after the linkage study was completed and carried the disease allele as well)). Family members’ DNA used for genome-wide SNP genotyping indicted
with black stars; additional family members’ DNA included for confirmation of linkage with microsatellite markers indicated in red stars. b. Histogram
of multi-point LOD scores along chromosome 10 shows a single chromosomal region with LOD scores .2 on chromosome 10q11. c. A heterozygous
missense mutation resulting in a G.A nucleotide change in the BMS1 gene was identified in all affected members with ACC in this family
(c.2789G.A). d. The c.2789G.A mutation results in a Arg-to-His amino acid change (p.R930H) of a conserved Arg residue in BMS1. e. The p.R930H
amino acid change affects an Arg residue within the putative C-terminal GAP domain of BMS1. Representative image of the domains of BMS1 with its
GTPase domain at the N-terminus (adapted from [9]). f. Murine embryonic sections showing the site of skin formation at the vertex area of the scalp
at E13.5 (f. and g.). BMS1 expression is seen in all cells, including the proliferative epidermis (C-terminus of BMS1 in red, pH3b green). C-term indicates
labeling with the monoclonal anti-BMS1 antibody that recognizes the C-terminus of BMS1. pH3b indicates staining for the proliferation marker
phospho-Histone 3B (Ser10) (pH3b, green). g. Co-localization of BMS1 C-terminal (C-term red) and N-terminal domains (N-term green) at E13.5 of
embryonic murine scalp at E13.5. Nuclei are labeled with DAPI. All images are acquired with a 206objective.
doi:10.1371/journal.pgen.1003573.g001
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PLOS Genetics | www.plosgenetics.org 3 June 2013 | Volume 9 | Issue 6 | e1003573Figure 2. ACC fibroblasts with mutated BMS1 show a delay in 18S pre-rRNA processing. a. Pre-rRNA processing pathways in human cells
(adapted from [33]). Two pathways coexist depending on the order of cleavage in the 59-ETS (sites A0 and A1) and ITS1 (A2). Nomenclature of the
cleavage sites follows Hadjiolova et al. (1993) and Rouquette et al. (2005) [33,34]. b. Pulse-chase labeling of pre-rRNAs with L-[methyl-
3H]methionine
shows that ACC
BMS1(p.R930H) fibroblasts (ACC) form all pre-rRNA species compared to control fibroblasts (WT), but retain increased 45S and 30S pre-
rRNAs (seen at 180 minutes after pulse-labeling). Relative values for bands normalized to 28S rRNA band are shown (fold-change compared to WT). c.
Magnification of 45S pre-rRNAs 180 minutes after pulse labeling shows retained 45S pre-rRNA in ACC
BMS1(p.R930H) fibroblasts compared to control
fibroblasts (WT). d. Northern blot analysis of pre-rRNA processing using a radioactive ITS-1 probe. RNA from ACC fibroblasts was used carrying the
BMS1 p.R930H mutation, as well as from control fibroblasts (WT). The Northern blot shown on the left side for the WT and ACC cells was exposed
overnight, while the image on the right side shows the same blot after a 4 hour exposure. In addition, RNA from fibroblasts stably transfected with an
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fibroblasts with the BMS1 p.R930H mutation show a link between a
mutation in a gene involved in ribosomal function and a G1/S phase
transition delay that results in a reduced cell proliferation rate.
To determine the molecular changes that are associated with a G1/
S phase transition defect and a reduced cell proliferation rate in ACC,
unbiased analyses of primary ACC
BMS1(p.R930H) fibroblasts compared
to control fibroblasts were performed using global gene expression
profiling and quantitative comparative proteomic experiments.
Global transcript and proteomic analyses in
ACC
BMS1(p.R930H) skin fibroblasts
Microarray gene expression experiments showed differential
expression of 459 genes (p-value,0.05, FDR,5%) between
ACC
BMS1(p.R930H) fibroblasts and cells obtained from an unaffected
unrelated individual (Table S1). Increased expression of p21
(CDKN1A) mRNA in ACC fibroblasts was noticed, which was
further confirmed by semiquantitative RT-PCR (Fig. 4a and 4b). The
cyclin-dependent kinase inhibitor p21 mediates a G1/S phase arrest in
response to cellular stress and other stimuli, and the increased p21
mRNA levels are consistent with the observed G1/S phase transition
delay in ACC fibroblasts. Western blotting experiments confirmed
increased p21 protein levels in ACC fibroblasts compared to control
fibroblasts, whereas total p53 protein levels were not significantly
increased (Fig. 4d). There was also no difference in p53
Lys342
acetylation and no p53
Ser15 phosphorylation was detected in ACC
fibroblasts (data not shown). These findings suggest a role for increased
p21 levels in the observed G1/S phase transition defect in ACC
fibroblasts. Serine/arginine-rich splicing factor 3 (SRSF3) was found to
be downregulated in ACC fibroblasts (Fig. 4a and 4b), which has
recently been reported to promote transcription of G1/S phase
checkpoint regulators and silencing of SRSF3 caused a G1/S phase
arrest (Kurokawa et al., EMBO meeting 2011 abstract).
Overexpression of the mutant BMS1 p.R930H in wild-type
fibroblasts resulted in increased transcript levels of p21 and
decreased SRSF3transcript levels, as observed in ACC
BMS1(p.R930H)
fibroblasts (Fig. 4c).
Next, a global quantitative comparative proteomic analysis was
performed using iTRAQ-labeling and subsequent MS analysis,
comparing control versus ACC early passage subconfluent fibroblasts.
Using stringent parameters for statistical significance, 25 proteins were
found to be consistently upregulated in ACC fibroblasts, whereas 18
were downregulated (Fig. 5a). Downregulated proteins in ACC
fibroblasts included several serine/arginine-rich splicing factors
(SRSF1, SRSF2, SRSF3, SRSF7), including SRSF3 that was also
downregulated in the microarray transcript profiling experiments.
Other downregulated proteins included heterogenous nuclear ribonu-
cleoproteins (HNRNPA2B1, HNRNPH2, HNRNPA1). Decreased
levels of hnRNPA2B1 in ACC fibroblasts were further confirmed by
Western blotting experiments (Fig. 5c). Importantly, hnRNPA2
knockdown has been shown to result in a p53-independent increase
of p21 levels and an inhibition of cell proliferation [13], as observed
here in ACC
BMS1(p.R930H) fibroblasts.
Functional enrichment analysis of the proteomic data ranked the
category ‘‘RNA post-transcriptional modification’’ as the top-ranked
cellular process altered in ACC fibroblasts (Benjamini-Hochberg
multiple test corrected p-value 4.72E-06). Network analysis identified
the two most significantly altered networks to include top functions for
‘‘RNA-posttranscriptional modification’’ and ‘‘cell cycle’’ (Fisher exact
test –lg p-value of 70 and 21 respectively) (Fig. 5b). Thus, the results of
the unbiased global proteomic analysis in ACC
BMS1(p.R930H) fibroblasts
are consistent with a defect in pre-rRNA processing. These two top-
ranked networks were merged to generate a combined network of the
differentially present proteins in ACC
BMS1(p.R930H) fibroblasts (Fig. 6a),
which were further analyzed for interactions with the differentially
expressed transcripts. This analysis revealed the highest number of
interactions to include p21 (CDKN1A) and hnRNPA2B1 (Fig. 6a).
Furthermore, interaction analysis among p21 and the entire merged
proteomic network revealed a central role of p21, suggesting that p21
activation is a central determinant of the ACC phenotype (Fig. 6b).
Discussion
Mutations in genes for structural proteins of the ribosome or in
other genes involved in ribosome biogenesis or function have been
inducible BMS1 shRNA vector was used, after shRNA-mediated knockdown of BMS1 transcripts was induced by doxycycline (doxy) treatment.
Ethidiumbromide stained gels prior to blotting (bottom) confirm equal loading of RNA. Quantitation of band intensity ratios expressed as relative
values (fold-change compared to WT or untreated cells). e. Doxycyline-inducible knockdown of BMS1 by shRNA lentivirus (shBMS1). Doxycycline
treatment for 48 hours results in ,60% reduction of BMS1 transcript levels. * P-value,0.05.
doi:10.1371/journal.pgen.1003573.g002
Figure 3. ACC fibroblasts with mutated BMS1 show a G1/S phase cell cycle transition delay and reduced cell proliferation rate. a.
Primary ACC fibroblasts show a significantly reduced proportion of cells in S-phase compared to control fibroblasts (WT), consistent with a delay in
G1/S phase transition in mutant cells. PI staining and FACS-based analysis. * P-value,0.05 for cells in G1 and S phase. b. Cell proliferation rate is
reduced in ACC fibroblasts. * P-value,0.05 for values between d4 to d7. c. In vitro scratch assay of fibroblasts on fibronectin-coated dishes show
increased cell migration rate in ACC fibroblasts (assayed at 14 hours after scratch). Images taken with a 2.56objective. * P-value,0.05. Graph shows
area not repopulated with fibroblasts.
doi:10.1371/journal.pgen.1003573.g003
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including Diamond Blackfan anemia (e.g. RPS19 and RPS24),
Shwachman-Diamond syndrome (SBDS), X-linked dyskeratosis
congenita (DKC1), cartilage hair hypoplasia (RMRP) and
Treacher Collins syndrome (TCOF1, POLR1C and POLR1D)
[14,15,16,17,18]. However, a disease phenotype in these disorders
may not always be a direct consequence of ribosomal dysfunction,
but may be due to other disease mechanisms. For example, in both
dyskeratosis congenita and cartilage hair hypoplasia ribonucleo-
protein complexes containing telomerase are involved, likely
critical to maintain stem cell function. RMRP, which is mutated
in cartilage hair hypoplasia, interacts with TERT (the catalytic
subunit of telomerase) and forms a ribonucleoprotein complex that
has RNA-dependent RNA polymerase activity [19]. DKC1,
mutated in X-linked dyskeratosis congenita, is associated with
small nucleolar RNAs, but also with human telomerase RNA
(TERC), and it has been suggested that the disease phenotype in
dyskeratosis congenita results from a defect in telomere mainte-
nance [20]. Thus, although these two diseases have been classified
as ribosomopathies, their pathologies may result from cellular
dysfunction that is not due to a ribosome biogenesis defect.
Notably, ribosomopathies manifest with very specific clinical
features affecting only few organ systems and often resulting in
hematologic and craniofacial abnormalities [21]. These specific
phenotypes affect particular cell types, despite the ubiquitous
expression of the mutated gene, and illustrate that a mutation in a
gene involved in ribosomal function that affects basic cellular
pathways can manifest with a selected clinical abnormality. In this
context, it is not surprising that despite the ubiquitous expression
of BMS1, individuals harboring the BMS1 p.R930H mutation in
non-syndromic ACC display only a localized skin morphogenesis
defect without further systemic anomalies. A mutation that slows
cell proliferation may manifest itself at an anatomic location that
requires rapid growth of a tissue compartment, such as the
embryonic skin at the vertex area during the rapid expansion of
the skull in embryonic development. As such, it is also not
surprising that aplasia cutis can be seen in various diverse
syndromes in which cell proliferation rate is affected in addition to
other basic cellular pathways that also affect other organ systems
and lead to multiple congenital anomalies. For example, Adams-
Oliver syndrome (AOS) patients have aplasia cutis and multiple
additional congenital anomalies, and skin fibroblasts from AOS
Figure 4. An increase in p21 levels in ACC skin fibroblasts. a. Microarray gene expression profiling experiments (experimental triplicates for
ACC vs control fibroblasts) show an upregulation of p21 mRNA levels and a downregulation of SRSF3 mRNA levels in ACC fibroblasts. b. These
findings were confirmed by semiquantitative RT-PCR. *P-values,0.05. c. Overexpression of mutant BMS1p.R930H in wild-type fibroblasts
phenocopies ACC fibroblasts in showing increased p21 and decreased SRSF3 transcript levels. *P-values,0.05. d. Western blotting experiments show
increased p21 protein levels in ACC fibroblasts compared to control fibroblasts, while p53 protein levels are not significantly changed. Relative values
for bands normalized to loading control are shown.
doi:10.1371/journal.pgen.1003573.g004
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(ARHGAP31) showed an enhanced cell migration rate and a
reduced cell proliferation rate in vitro, as seen here in
ACC
BMS1(p.R930H) fibroblasts [3].
Several studies have shown that ribosomal gene mutations can
lead to ‘‘nucleolar stress’’ and a G1/S phase cell cycle arrest both
via p53-dependent and p53-independent mechanisms that are
only partially understood [21,22]. It has been proposed that the
ribosomal stress response, as a consequence of alterations in
ribosomal assembly or processing, results in increased free
ribosomal proteins that can either inactivate Mdm2, resulting in
p53 accumulation and p21-mediated cell cycle arrest, or increase
p27 levels that ultimately result in a cell cycle arrest [11].
Consistent with these findings in some ribosomopathies, ACC
fibroblasts with the BMS1 p.R930H mutation showed a G1/S
phase cell cycle transition defect associated with increased p21-
levels that result in a reduced cell proliferation rate.
BMS1 function has been studied mostly in yeast, demonstrating
that inducible depletion of BMS1 in yeast results in inhibition of
pre-rRNA processing at sites A0,A 1 and A2 affecting the small
ribosomal subunit processome [7,8,9,10], while little is known
about the function of BMS1 in vertebrates. The data presented
here are consistent with the findings in yeast and suggest that
reduced BMS1 function delays maturation of the 18S rRNA in
human cells.
A homozygous mutation in the GTPase domain of BMS1 has
recently been reported to result in impaired liver development in
zebrafish, while heterozygosity for this mutation does not cause an
Figure 5. Global proteomic analysis in ACC skin fibroblasts. a. Comparative quantitative proteomic analysis with iTRAQ labeling experiments.
Upregulated proteins in ACC fibroblasts are shown in the upper part of the figure and downregulated proteins in the lower part of the figure. The
columns show values for the following: Peptides (95%): number of peptides identified with at least 95% confidence; raw p-value; false discovery rate
(FDR), fold change of WT vs ACC mean values. b. Network analysis (Ingenuity) identified the most significantly altered networks to include top
functions for ‘‘RNA-posttranscriptional modification’’, ‘‘protein synthesis’’ and ‘‘cell cycle’’ (Fisher exact test –lg p-values indicated). c. Western blotting
experiments confirm downregulation of hnRNPA2B1 in ACC fibroblasts compared to control fibroblasts. Relative values for bands normalized to
loading control are shown.
doi:10.1371/journal.pgen.1003573.g005
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BMS1 and other components of the small subunit processome in
liver development, which is further supported by the identification
of homozygous mutations in the gene cirhin in North American
Indian childhood cirrhosis that is required for proper 18S rRNA
maturation [24,25].
The heterozygous BMS1p.R930H mutation in ACC is
located in the putative regulatory GAP domain, and therefore
is likely to affect BMS1 function to a lesser degree than the
homozygous mutation in the GTPase domain of BMS1 in
zebrafish. In this context, it is not surprising that patients with
autosomal dominant ACC do not display major developmental
liver abnormalities. Instead, the data presented here show a
developmental localized skin formation defect at a site of rapid
expansion of the skin due to a heterozygous mutation in the
putative GAP domain of BMS1, which provides the first
human mutation for BMS1.
Through which exact mechanisms this mutation causes a p21-
mediated G1/S phase arrest and is correlated with the observed
downregulation of hnRNPs and SRSFs remains to be determined
in future studies. The reported observation that hnRNPA2
knockdown results in a p53-independent increase of p21 levels
and an inhibition of cell proliferation [13], similar as observed here
in ACC
BMS1(p.R930H) fibroblasts, together with the results form the
interaction analyses of the proteomic data that show the largest
number of interactions to involve p21 and hnRNPA2B1 in ACC
fibroblasts, suggest that the reduced protein levels of hnRNPA2B1
likely play a role in ACC pathogenesis.
During embryonic development p21 expression correlates with
arrest of cell proliferation and is found in postmitotic cells
immediately adjacent to the proliferative compartment, as in the
outer embryonic epidermis and particularly in the developing hair
follicles [26,27]. Notably, p21 expression is decreased in terminally
differentiated cells and overexpression of p21 inhibits late stages of
differentiation of keratinocytes and the stem-cell potential of
keratinocyte subpopulations [28,29]. Thus, the increased p21
levels in ACC may result in an inhibition of cell proliferation as
well as an inhibition of terminal differentiation of the outer
epidermis during embryonic development, and explain the
observed skin morphogenesis defect in ACC. Increased p21 levels
have also been linked to increased scar formation, which is
consistent with the prominent hypertrophic scar formation in
patients with ACC, as was also observed in affected members of
this family (Fig. 1a) [30].
In summary, the findings in this study show that the BMS1
p.R930H mutation is associated with a downregulation of
hnRNPA2B1 (and other hnRNPs and SRSFs) and a p21
upregulation, leading to a G1/S cell cycle phase transition delay
and an inhibition of cell proliferation. The data presented here
provide a novel link between BMS1, a p21-mediated cell cycle
arrest and skin morphogenesis.
Materials and Methods
Patients and samples
A five-generation family was identified with autosomal domi-
nant inheritance of ACC. All participants provided written
consent, and the Institutional Review Board of Massachusetts
General Hospital approved this study. Genomic DNA was
extracted from peripheral blood lymphocytes using the QIAGEN
Puregene blood isolation kit (Qiagen). DNA concentrations were
determined using the Picogreen assay (Life Technologies).
Genome-wide SNP and microsatellite genotyping and
linkage analysis
Genomic DNA from individuals of this family were prepared,
labeled and hybridized to the Affymetrix Genome-Wide Human
SNP array 6.0, which features more than 906,000 SNPs. SNP data
was analyzed with the Affymetrix Genotyping Console. Merlin
version 1.1.2 was used for parametric linkage analysis [31].
Linkage analysis was performed with either 100% or 95% disease
penetrance, equal or calculated allele frequencies, and various
disease allele frequencies. The frequency of ACC in the population
has been estimated to be about 1:30,000 births. Independently,
microsatellite genotyping was performed using informative mark-
ers from A&B Biosciences that spanned chromosome 10.
Targeted capture and massive parallel sequencing
About 10 mg of DNA from one affected individual of this family
was used for exome capture using the Agilent Sure select 50 Mb
kit. Sequencing was performed on an Illumina HiSeq 2000
sequencer. Reads were mapped to the UCSC hg19 reference
human genome. Sequence data was analyzed and variants were
filtered using the DNAnexus software package.
Sequence validation
Bidirectional Sanger sequencing of PCR amplicons from
genomic DNA was used to confirm the presence and identity of
variants identified via exome sequencing.
Cell culture and immunocytochemistry
Primary fibroblasts were obtained from a family member with
ACC (p.R930H) through a 4 mm abdominal skin biopsy. Control
fibroblasts were obtained from a skin biopsy of a matched
unrelated individual without ACC (matched for anatomic
location, skin phototype, and age). The skin biopsy sample was
treated with collagenase I, and subsequently fibroblasts were
maintained in culture in DMEM (Invitrogen) with 20% fetal calf
serum (Sigma) and antibiotic/antimycotic (Invitrogen).
For cell immunolabeling experiments, fibroblasts were grown
on poly-L-lysine coated glass slides (BD Biosciences) and fixed with
methanol. Primary antibodies used were as follows: polyclonal
rabbit BMS1 (Sigma), monoclonal mouse BMS1 (Santa Cruz),
rabbit polyclonal nucleophosmin (Invitrogen), rabbit polyclonal
anti-phospho Histone H3 (Ser10) (Millipore). Secondary antibod-
ies used were fluorescently labeled Alexa antibodies from
Invitrogen. Nuclei were stained with DAPI. Mouse embryos at
E13.5 were fixed in 4% PFA and embedded in OCT and
cryosections were used for immunofluorescence experiments. F-
actin labeling was performed with phalloidin-Alexa Fluor 488
conjugates (Invitrogen). Microscopy was performed with a Zeiss
Axiovert microscope.
Figure 6. Comparative proteomics and global gene expression profiling reveals a central role of p21 activation in ACC. a. The two
top-ranked networks were merged to generate a combined network of the differentially present proteins in ACC fibroblasts (center). Differentially
expressed genes identified in the transcript profiling microarray experiments are indicated in the periphery of the proteomic network, and
interactions are illustrated by arrows. This analysis revealed the highest number of interactions to include p21 (CDKN1A) and hnRNPA2B1. b.
Interaction analysis among p21 (CDKN1A) and the entire merged proteomic network revealed a central role of p21, showing that p21 activation is a
central determinant of the ACC phenotype.
doi:10.1371/journal.pgen.1003573.g006
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mutant BMS1 in fibroblasts
In vitro mutagenesis was performed according to the manufac-
turers protocol (Stratagene). Mutant (c.2789G.A) and wild-type
BMS1 cDNA was cloned into the pEGFPN1 (Clontech) expression
vector, fusing EGFP at the C-terminus of the expressed cDNA.
Primary human wild-type fibroblasts that were used as controls in
all experiments (matched for age-, anatomic location and skin
phototype) were transfected in triplicate with purified plasmid
using XtremeGene HP DNA transfection reagent (Roche) or
nucleofection using the Amaxa human dermal fibroblast nucleo-
fector kit with program U-023 (Amaxa). Expression and subcel-
lular localization of the expressed EGFP-tagged protein was
evaluated on a Zeiss Axiovert fluorescence microscope. For
semiquantitative RT-PCR experiments, transfected fibroblasts
(n=3 independent transfections) were sorted for EGFP 48 hours
after transfection using a cell sorter (MoFlo) and RNA was
immediately isolated after sorting with Trizol reagent (Invitrogen).
Overexpression was confirmed by semiquantitative RT-PCR for
BMS1 transcript levels. All experiments were performed in
triplicate.
Cell cycle analysis
Cell cycle analysis with propidium iodide was performed
according to standard protocols. Briefly, subconfluent fibroblasts
were fixed in 70% ethanol, treated with RNase A and stained with
propidium iodide (Sigma) and cell cycle status was determined by
FACS analysis and subsequent analysis by FlowJo software
(version 9.4.9) using the Watson pragmatic model for determina-
tion of cell cycle phases. Experiments were performed in triplicate
for ACC and WT cells.
Cell proliferation assay
The CyQUANT fluorescence-based microplate assay was used
for quantitation of cell numbers and used according to the
manufacturers protocol (Invitrogen). Binding to cellular nucleic
acids was measured by using 485 nm excitation and 530 nm
emission filters with a fluorescence microplate reader. The
fluorescence emission of the dye-nucleic acid complexes was then
correlated linearly with cell numbers from a dilution series of cells
that were collected d2–d7 after cell culture of equal numbers of
cells. For each time point triplicate experiments were performed.
In vitro cell migration assay
Cell migration assays were performed with WT and
ACC
BMS1(p.R930H) primary dermal fibroblasts plated on fibronec-
tin-coated 6 cm
2 tissue culture dishes (n=3/group). Cells were
serum- and growth-supplement- starved for 12 hours before
inducing a linear scratch wound with a 1 ml pipette tip. Cultures
were washed twice with PBS, and wound margins were
photographed. The same wound margin fields were photographed
after 14 hours, and the scratch areas that were not repopulated by
fibroblasts were measured with Zeiss Axiovision software. Similar
findings were obtained when dishes were coated with collagen.
Western blotting
Western blotting was performed with 50 mg of total protein
lysate from subconfluent early passage ACC and control
fibroblasts. Protein concentrations were determined by a standard
Bradford assay. NP-40 lysis buffer and complete protease inhibitor
cocktail (Roche) was used. NuPage Bis-Tris 4–12% gradient gels
were used. Primary antibodies used were: mouse monoclonal anti-
p53 (clone DO-1) (Becton Dickson), rabbit polyclonal anti-b-actin
(Thermo), rabbit anti-p21 polyclonal antibody (Thermo Fisher)
and mouse anti-HNRNPA2B1 (Millipore). HRP-conjugated sec-
ondary antibodies were used from GE. b-actin loading control was
performed on each blot. Band intensities were quantified using
NIH ImageJ software (NIH, version 1.46).
Pulse-chase labeling of rRNA with L-
[methyl-
3H]methionine
To study the kinetics of pre-rRNA processing pulse-chase
labeling with L-[methyl-
3H]methionine was performed on early
passage subconfluent ACC
BMS1(p.R930H) fibroblasts and control
fibroblasts as described [32]. Briefly, cells were cultured on 6-well
plates and after being cultured for 15 minutes in methionine-free
medium, cells were pulsed with L-[methyl-
3H]methionine at a final
concentration of 50 mCi/ml for 30 minutes. 106 methionine
medium was used for the chase and total RNA was isolated with
Trizol (Invitrogen) at 0, 15, 45, 60 and 180 minutes after the end
of the pulse. 1 mg of total RNA was loaded on a 1% formaldehyde-
agarose gel and after electrophoresis blotted overnight on a nylon
membrane (Ambion). Signal intensity was increased with the
EN
3HANCE spray (PerkinElmer Life) and treatment with carbon
tetrachloride (Sigma) as described [32]. The nylon membrane was
exposed to Kodak BioMax MS high-sensitivity radiography film
(Kodak).
Comparative proteomic analysis with multiplex iTRAQ
Early-passage fibroblasts isolated from an affected individual
with ACC from this family with the BMS1 mutation p.R930H
were used for comparative proteomic analysis. Fibroblasts,
matched for ethnicity and anatomic location, were used as
control. From each individual fibroblasts were used as quadrupli-
cate experimental samples in a 8-plex iTRAQ experiment. Whole
cell lysates were generated using Pressure Cycling technology.
Collected cells were resuspended in RIPA buffer plus Pefablock
(Roche complete tabs, 1 tablet per 10 ml) and 1 mM DTT. The
cells were then lysed in a Barocyler NEP2320 instrument from
Pressure Biosciences, Inc. (South Easton, MA). Following lysis,
proteins were recovered by acetone precipitation. Acetone
precipitated material that resuspended in milliQ water was used
as the soluble protein extract. Protein concentrations were
determined using the Bio-Rad Protein Assay with BSA used to
generate a standard curve. The 8-plex iTRAQ assay for
multiplexed relative quantitation (AB SCIEX, Foster City, CA)
was used to determine the protein level differences between
control and ACC cells. Briefly, equal amounts of soluble protein
from each fibroblast experimental group (100 mg) was dried in a
speed vacuum/centrifuge. Following the recommended 8-plex
iTRAQ protocol, dried proteins were resuspended in 21 mlo f
500 mM TEAB (pH 8.5), 0.1% SDS. Proteins were then reduced
with 5 mM TCEP by incubation at 55uC for 1 hour. Reduced
disulfide bonds were then blocked by adding a final concentration
of 8 mM MMTS and incubating at room temperature for 10 min.
Peptides were generated in each sample by overnight digestion
with trypsin (AB SCIEX) added at a ratio of 1:10. Samples were
then labeled with the 8-plex iTRAQ reagent. Confirmation of
efficient label attachment was confirmed by MS/MS in an AB
SCIEX 4800 MALDI-TOF/TOF before samples were pooled
into one.
Half of the sample (,400 mg) was processed using standard
MuDPIT methodology to maximize protein identification. First
dimension strong cation exchange (SCX) separation was per-
formed on an Agilent 1100/1200 HPLC with a POROS HS/20
column (4.66100 mm, AB SCIEX). 40 fractions covering the
eluted peptides were then individually run for second dimension
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a C18 Acclaim PepMap100 column (75 mm615 cm, 3 mm beads).
Approximately 500 spots were printed per fraction to 4800
MALDI plates (5 SCX fractions per plate) with CHCA (5.0 mg/
ml) mixed in by the ProBot in a mixing Tee immediately before
printing. MS and MS/MS on the peptides were performed in the
AB SCIEX 4800 mass spectrometer.
Proteomic data analysis
Relative abundance quantitation and peptide and protein
identification were performed using ProteinPilot software 3.0
(Applied Biosystems). The Swiss-Prot Homo sapiens protein
database (Swiss-Prot/UniProt) was used for all searches. The data
were normalized for loading error by bias analysis using
ProteinPilot.
The high confidence proteins are defined as those with (a)
.90% confidence as determined by ProteinPilot (ProtScore $1.0)
and (b) two distinct peptides with different iTRAQ spectra
identified with $95% confidence. These high confidence proteins
were identified using Perl and R scripts. The differentially present
proteins were identified by comparing the relative weighted
average iTRAQ values of proteins in the control and ACC groups.
The significance of differential levels of protein iTRAQ ratios was
determined using the multiple test corrected (FDR) P-value.
Proteins that had a iTRAQ ratio .1.2 or ,0.80 (calculated on
basis of variance in iTRAQ values), a raw P-value of ,0.05 and a
FDR,10% between control and ACC groups were considered
differentially present.
Interactive networks and pathways were analyzed using the
Ingenuity Pathways Analysis package (IPA 4.0) (http://www.
ingenuity.com/). It calculates the P-value for each network, and
function according to the fit of user’s data to IPA database. It
displays the results as Fisher’s exact test -lg P-value indicating the
likelihood of a gene to be found in a network or function by
random chance.
Microarray transcript analyses and semiquantitative RT-
PCR
Early-passage fibroblasts isolated from an affected individual
with aplasia cutis from this family with the BMS1 mutation
p.R930H and control fibroblasts, matched for ethnicity and
anatomic location (but not for gender), were each used as triplicate
experimental samples in gene expression analysis experiments
(which were also used in the comparative proteomic analysis).
Total RNA was isolated from fibroblasts using the RNEasy Plus
kit (Qiagen), and treated with DNAse. Semiquantitative RT-PCR
was performed using the total RNA. cDNA was generated using
the Transcriptor First Strand cDNA synthesis kit with random
hexamer primers (Roche). Semiquantitative RT-PCR was per-
formed using the LightCycler 480 DNA SYBR-Green I Master kit
on a LightCycler 480 (Roche Applied Science). The following
primers were used: p21 (up: GCAGACCAGCATGACAGATTT;
dw: GGATTAGGGCTTCCTCTTGGA). Pretested SRSF3 and
BMS1 qPCR primers were used from SABiosciences (Qiagen) and
results were normalized to 36B4 transcript levels. Reactions were
performed in triplicate (n=3) and also three times for each
sample.
Human Genome U133 Plus 2.0 Affymetrix microarrays were
used for global gene expression profiling experiments. Obtained
raw data was analyzed using the dCHIP software (https://sites.
google.com/site/dchipsoft/). Differential expression was deter-
mined significant with dCHIP with a P-value,0.05 and a false
discovery rate (FDR) ,5% among the control (WT) and ACC
groups (samples in triplicate for each group; corrected for gender).
Inducible knockdown of BMS1
To achieve a stable partial inducible knockdown of BMS1 a
puromycin-selectable TRIPZ doxycycline-inducible lentiviral
shRNA system was used, which allows for the detection of
shRNA-mediated gene silencing by TurboRFP expression (Open
Biosystems). TRIPZ BMS1 shRNA clone V3THS_361658 was
used to transfect wild-type fibroblasts and cells were selected by
puromycin treatment. Fluorescence microscopy confirmed that
after puromycin treatment all remaining cells were expressing
TurboRFP. After 48 hours treatment with 1 mg/ml doxycycline
RNA was isolated from these stably transfected cells to obtain
cDNA. Semiquantitative RT-PCR for BMS1 confirmed a ,50–
60% knockdown of BMS1 transcript levels and cDNA was used
for semiquantitative RT-PCR of p21 and SRSF3 transcript levels.
As controls these cells were used in the absence of doxycycline
treatment. From each group experiments were performed in
triplicate. Total RNA was used for Northern Blot analyses.
Northern blotting
Northern blotting was performed as described previously [32].
From each sample 2 mg total RNA was loaded on a 1.2%
formaldehyde-agarose gel and blotted on a positively charged
Nylon membrane (BrightStar-Plus, Ambion). Radioactive probes
labeled with [c-
32P]ATP for ITS-1, ETS-1 and ITS-2 were used as
described previously [33]. Band intensities were quantified using
NIH ImageJ software (NIH, version 1.46).
Supporting Information
Figure S1 a. Transient transfection of EGFP-tagged full-length
mutant (c.2789G.A) and wild-type BMS1 (b.) in control fibroblasts
shows nucleolar localization. Thus, the mutation does not affect
subcellular localization of BMS1. c.–h. Immunofluorescence labeling
of subconfluent ACC and control fibroblasts. c. BMS1 maintains its
nucleolar localization (green, N-term) and co-localizes with nucleo-
phosmin (red) as seen in control cells (d. WT). N-term indicates labeling
with the polyclonal anti-BMS1 antibody recognizing the N-terminus of
BMS1. E–f. Labeling of the C-terminal (C-term, red) and N-terminal
domain of BMS1 (N-term, green) shows nucleolar co-localization in
ACC (e.) and control fibroblasts (f.). C-term indicates labeling with the
monoclonal anti-BMS1 antibody that recognizes the C-terminus of
BMS1. g. ACC and control fibroblasts (h.) maintain their ability to
proliferate and show staining for the proliferation marker phospho-
Histone 3 (Ser10) (pH3b, green). BMS1 expression in red (C-term). i.–j.
Phalloidin staining shows no major difference of the actin cytoskeleton
in ACC and control cells. Nuclei are labeled with DAPI. All images are
acquired with a 206objective. k. Semiquantitative RT-PCR shows no
significant difference of BMS1 expression in ACC and control cells
(BMS1 transcript levels normalized to 36B4 transcript levels; P-
value.0.05).
(PDF)
Figure S2 Northern blot analysis of pre-rRNA processing using
radioactive ETS-1 and ITS-2 probes. RNA from ACC fibroblasts
was used carrying the BMS1 p.R930H mutation, as well as from
control fibroblasts (WT). RNA from fibroblasts stably transfected
with an inducible BMS1 shRNA vector was used, after shRNA-
mediated knockdown of BMS1 transcripts was induced by
doxycycline (doxy) treatment. Ethidiumbromide stained gels prior
to blotting (bottom) confirm equal loading of RNA. Quantitation
of band intensity ratios expressed as relative values (fold-change
compared to WT or untreated cells). The 12S bands shown for the
ITS-2 Northern blot in WT and ACC cells were exposed longer to
reveal discernable bands.
(PDF)
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early-passage fibroblasts derived from an affected individual with
ACC (BMS1p.R930H) and a matched healthy control individual.
Transcripts that are at least 1.2-fold differentially expressed are
indicated (P-value,0.05).
(PDF)
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